Marta Lozano Sanz Diez de Ulzurrun

CHAIN Biotechnology was founded in 2014, by serial entrepreneur Dr Edward Green, to exploit the therapeutic potential of Clostridia bacteria found in the human gut microbiome. CHAIN has built an impressive technical team of molecular biology, microbiology, microbiome and fermentation specialists focused on the biotechnology development of Clostridia. In addition, CHAIN leverages synthetic biology expertise from the Synthetic Biology Research Centre at the University of Nottingham. CHAIN has developed a proprietary microbial platform for drug delivery. The platform builds on core engineering skills and involves the development and use of engineered Clostridia to deliver specific therapeutics to the gut. CHAIN’s Clostridium Assisted Drug Delivery (CADD™) delivery platform is highly differentiated and supports a therapeutic product pipeline for a wide range of clinical indications including localised infection, inflammation and CNS signalling. Our lead asset is an engineered strain that secretes a novel and potent anti-inflammatory molecule targeting Inflammatory Bowel Disease, a chronic gut disease affecting millions worldwide.

Ceryx Medical are an exciting new Medtech company developing a range of innovative bioelectronic devices. These devices use a unique chip technology which is able to mimic nerve centres within the body called central pattern generators. These CPGs help to control a range of autonomic or rhythmical processes such as peristalsis, heart rate and even walking. It is hoped that Ceryx’s artificial CPGs can restore normal performance where these processes have been affected by disease or injury.

CHAIN Biotechnology was founded in 2014, by serial entrepreneur Dr Edward Green, to exploit the therapeutic potential of Clostridia bacteria found in the human gut microbiome. CHAIN has built an impressive technical team of molecular biology, microbiology, microbiome and fermentation specialists focused on the biotechnology development of Clostridia. In addition, CHAIN leverages synthetic biology expertise from the Synthetic Biology Research Centre at the University of Nottingham. CHAIN has developed a proprietary microbial platform for drug delivery. The platform builds on core engineering skills and involves the development and use of engineered Clostridia to deliver specific therapeutics to the gut. CHAIN’s Clostridium Assisted Drug Delivery (CADD™) delivery platform is highly differentiated and supports a therapeutic product pipeline for a wide range of clinical indications including localised infection, inflammation and CNS signalling. Our lead asset is an engineered strain that secretes a novel and potent anti-inflammatory molecule targeting Inflammatory Bowel Disease, a chronic gut disease affecting millions worldwide.

BGF is the UK and Irelands most active growth investor, backing ambitious businesses with minority investment to help them scale on their own terms. Since 2011, we have invested more than £5bn in 650+ businesses across every region and sector. Today, with more than £3.5bn in assets under management, we continue to support a range of growing companies across early-stage and growth-stage. Through our 15 offices across the UK and Ireland, were close to the businesses we back, combining local insight with national scale to build trusted partnerships with entrepreneurs and management teams. Beyond investment, our portfolio companies benefit from the expertise of our 200+ strong team, as well as dedicated value creation support spanning talent, operational expertise and our Scale community – including a network of more than 8000+ experienced business leaders, sector specialists and board-level non-executives. Learn more: BGF UK: https://www.bgf.co.uk BGF Ireland: https://www.bgfireland.ie/

Ceryx Medical are an exciting new Medtech company developing a range of innovative bioelectronic devices. These devices use a unique chip technology which is able to mimic nerve centres within the body called central pattern generators. These CPGs help to control a range of autonomic or rhythmical processes such as peristalsis, heart rate and even walking. It is hoped that Ceryx’s artificial CPGs can restore normal performance where these processes have been affected by disease or injury.

ELAVITY is an #oxford based incubator, venture building & investment firm focused on early stage (Seed & Series A) development of #therapeutic and #medtech startups. Our strategic focus is on academic spin outs and startups in UK, Europe, USA & Australia. We run two incubation programmes with modules on IP, Regulatory, Legal, Team Building and ending in Pitch Event. In each pitch event 10-15 leading lifescience venture capital company attends including major #therapeutic, #medtech VCs. If you are interested get in touch & apply for the next cohort.